Evaluation of Explanted Lungs by MRI and Biological Assays

(Xe MRI in ILD Trial)

Overseen By Jason Woods, PhD

Age: 18+

Sex: Any

Trial Phase: Academic

Sponsor: Children's Hospital Medical Center, Cincinnati

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Compensation: Varies

Number of Visits: Unknown

100 Participants Needed

Trial Summary

What is the purpose of this trial?

The purpose of this multi-centered, NIH-sponsored study is to to develop an optimal protocol for using non-invasive 129Xe gas exchange MRI to detect changing disease activity in interstitial lung diseases (ILDs). We base this study on the demonstrated promise of 129Xe as a biomarker for both prognosis and therapy response, overwhelming interest from both industry and academic partners, and impending FDA approval for 129Xe ventilation MRI. This requires disseminating standardized and repeatable methods for 3D 129Xe functional MRI in order to facilitate innovative multi-center observational and interventional trials that can advance our understanding of fibrotic lung disease, while accelerating the development of novel therapies.

Research Team

Jason Woods, PhD

Principal Investigator

Children's Hospital Medical Center, Cincinnati

Eligibility Criteria

Inclusion Criteria

You are agreeable to provide informed permission and comply with visit/protocol timelines (Permission must be obtained prior to any research activities being executed.)

You are an adult (age >18) of either gender and not hospitalized.

You have been clinically diagnosed with Interstitial Lung Disease by a certified pulmonologist, according to established standards

Treatment Details

Participant Groups

Group I: ILD Experimental Treatment 1 Intervention

Participants with diagnosed ILD

Group II: Control Experimental Treatment 1 Intervention

Healthy Controls

Who Is Running the Clinical Trial?

Children's Hospital Medical Center, Cincinnati

Lead Sponsor

Trials

844

Recruited

6,566,000+